Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242608 | 1.00 | CYP1A2 (0.44) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL14683926 | 0.88 | CYP1A2 (0.44) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL30515102 | 0.88 | CYP1A2 (0.44) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL30946653 | 0.86 | CYP1A2 (0.43) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL217060 | 0.86 | CYP1A2 (0.43) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL2975188 | 0.83 | CYP3A4 (0.44) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL30987781 | 0.83 | CYP3A4 (0.44) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL12354205 | 0.80 | CYP1A2 (0.42) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL19171923 | 0.80 | MERTK (0.42) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 | |
| SCHEMBL19171917 | 0.80 | MERTK (0.42) | CYP1A2HSD17B10ALDH1A1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637925-A1 | INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2024178390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024133220-A1 | INHIBITORS OF α-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133220-A1 | INHIBITORS OF α-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-6479503-B2 | SUCH AS 2-(S/R)-2-(4-(2,4-DIMETHYL-5,6,7,8-TETRAHYDRO-ALPHA-CARBOLIN-9-YL)METHYL -PHENYL)-2-CYCLOPENTYL-ACETIC ACID N-((R)PHENYLGLYCINOAMIDE) FOR TREATING ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | MUELLER ULRICH (DE) | 2002-10-10 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | MULLER ULRICH (DE) | 2002-05-09 | — | — | US | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| US-6265431-B1 | ANTICHOLESTEROL DRUGS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-24 | — | — | US | disclosed |
| US-6245775-B1 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| US-5684014-A | FOR TREATING ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0705831-A2 | Cycloalkano-indole- and -azaindole derivatives | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP1A2 4794/4885HSD17B10 1835/4885ALDH1A1 4692/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CYP1A2 139/4885HSD17B10 810/4885ALDH1A1 588/4885 |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | AADAC, IDO1, AADAT | CYP1A2 277/4885HSD17B10 881/4885ALDH1A1 1034/4885 |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | ADRB3, AADAT, INMT | CYP1A2 244/4885HSD17B10 777/4885ALDH1A1 1445/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP1A2 4794/4885HSD17B10 1835/4885ALDH1A1 4692/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | CYP1A2 1271/4885HSD17B10 3134/4885ALDH1A1 1286/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | CYP1A2 4794/4885HSD17B10 1835/4885ALDH1A1 4692/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP1A2 4794/4885HSD17B10 1835/4885ALDH1A1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.